GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Compass Pathways PLC (NAS:CMPS) » Definitions » GF Score

Compass Pathways (Compass Pathways) GF Score : 41/100 (As of Apr. 29, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Compass Pathways GF Score?

Compass Pathways has the GF Score of 41, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 7/10
2. Profitability Rank : 1/10
3. Growth Rank : 0/10
4. GF Value Rank : 0/10
5. Momentum Rank : 10/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Compass Pathways might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Competitive Comparison of Compass Pathways's GF Score

For the Medical Care Facilities subindustry, Compass Pathways's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Compass Pathways's GF Score Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Compass Pathways's GF Score distribution charts can be found below:

* The bar in red indicates where Compass Pathways's GF Score falls into.



Compass Pathways  (NAS:CMPS) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.


Compass Pathways GF Score Related Terms

Thank you for viewing the detailed overview of Compass Pathways's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Compass Pathways (Compass Pathways) Business Description

Traded in Other Exchanges
Address
33 Broadwick Street, London, GBR, W1F 0DQ
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
Executives
Ekaterina Malievskaia officer: Chief Innovation Officer C/O COMPASS PATHWAYS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
George Jay Goldsmith director, 10 percent owner, officer: Chief Executive Officer C/O COMPASS PATHWAYS PLC, 1 ASHLEY ROAD, 3RD FLOOR, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Mary-rose Hughes officer: Interim CFO C/O COMPASS PATHWAYS PLC, 33 BROADWICK STREET, LONDON X0 W1F0DQ
Daphne Karydas director 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
Kabir Nath director, officer: Chief Executive Officer C/O COMPASS PATHWAYS PLC, 33 BROADWICK STREET, LONDON X0 W1F 0DQ
Annalisa Jenkins director C/O ARDELYX, INC., 34715 ARDENWOOD BLVD, SUITE 100, FREMONT CA 94555
David Y Norton director 8 GREENHOLM STREET, APT C, PRINCETON NJ 08540
Matthew A Owens officer: General Counsel & CLO 1900 POLARIS PARKWAY, COLUMBUS OH 43240
Atai Life Sciences Ag 10 percent owner KRAUSENSTRASSE 9-10, BERLIN 2M 10117
Atai Life Sciences N.v. 10 percent owner 524 BROADWAY, NEW YORK NY 10013
Linda Mcgoldrick director C/O AVADIM HEALTH, INC., 81 THOMPSON STREET, ASHEVILLE NC 28803
Jason Camm director C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014
Robert Mcquade director C/O COMPASS PATHWAYS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Michael Falvey officer: Chief Financial Officer C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, 2ND FLOOR, NEWTON MA 02459
Guy Goodwin officer: Chief Medical Officer C/O COMPASS PATHWAYS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT